COMPANY RESEARCHLegend Biotech Corporation
Legend Biotech is a publicly traded biotechnology company focused on developing and commercializing engineered cell therapies, particularly chimeric antigen receptor T-cell approaches. Its drug development combines cell engineering, translational science, clinical studies and commercial collaborations. The company has a major United States operating presence and a global headquarters in Bridgewater, New Jersey, while its listed issuer has a separate corporate legal structure. Legend trades on Nasdaq under LEGN. Its work centers on cancer therapies, including hematologic malignancies, with additional research into next-generation cell approaches.
Company at a glance
Corporate information
- Company entity
- Legend Biotech
- Headquarters / principal office
- Bridgewater, New Jersey, USACorporate website explicitly identifies headquarters; location follows the retrieved disclosure.
Sources (1)
- Legend Biotech official global headquartersChecked 2026-11-04; source publication date retained where stated
- Founded
- 2014
Sources (1)
- Legend official corporate history2026-11-04 retrieval; historical date as stated
- Ownership / capital status
- Publicly tradedPublicly traded (Nasdaq: LEGN); public-market transactions tracked separately
Sources (1)
- Corporate ownership / financing disclosureChecked 2026-11-04; source publication date retained where stated
- Official corporate reference
- https://legendbiotech.com/
Sources (1)
- Legend Biotech — official company page2026-11-04 retrieval; page undated unless stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Legend Biotech — official company page2026-11-04 retrieval; page undated unless stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Legend Biotech is a publicly traded biotechnology company focused on developing and commercializing engineered cell therapies, particularly chimeric antigen receptor T-cell approaches. Its drug development combines cell engineering, translational science, clinical studies and commercial collaborations. The company has a major United States operating presence and a global headquarters in Bridgewater, New Jersey, while its listed issuer has a separate corporate legal structure. Legend trades on Nasdaq under LEGN. Its work centers on cancer therapies, including hematologic malignancies, with additional research into next-generation cell approaches.
Nasdaq: LEGN
CAR-T · engineered cell therapy
hematologic oncology · cancer
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
LB2501 is a CD19/CD20 in vivo CAR-T candidate using the TaVec lentiviral platform, with an ongoing China Phase 1 study (NCT07002112). Its October 2026 U.S. IND clearance supports a planned Phase 1/2 study. Neither IND clearance nor early responses constitute approval.
Business, technology & evidence
- Legend Biotech is a publicly traded biotechnology company focused on developing and commercializing engineered cell therapies, particularly chimeric antigen receptor T-cell approaches. Its drug development combines cell engineering, translational science, clinical studies and commercial collaborations. The company has a major United States operating presence and a global headquarters in Bridgewater, New Jersey, while its listed issuer has a separate corporate legal structure. Legend trades on Nasdaq under LEGN. Its work centers on cancer therapies, including hematologic malignancies, with additional research into next-generation cell approaches.
- SecuritiesNasdaq: LEGN
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| LB2501 | CD19/CD20 · See program source; distinguish indications | Phase 1 | Human research disclosed or registered; efficacy is not established. |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Unverified financing, founding dates, and clinical status are not inferred. Acquisitions/options are not financing rounds.
- Legend Biotech — primary program / ownership disclosure ↗Legend Biotech · Undated unless stated in source; checked 2026-11-04
- Legend Biotech — supporting primary disclosure ↗Legend Biotech · Undated unless stated in source; checked 2026-11-04
- Official issuer and R&D disclosure · Legend Biotech Corporation ↗Legend Biotech Corporation ·
- Legend Biotech — official company page ↗Legend Biotech · 2026-11-04 retrieval; page undated unless stated
- Legend official corporate history ↗Legend Biotech · 2026-11-04 retrieval; historical date as stated
- Corporate ownership / financing disclosure ↗Legend Biotech · Checked 2026-11-04; source publication date retained where stated
- Legend Biotech official global headquarters ↗Legend Biotech · Checked 2026-11-04; source publication date retained where stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.